[logo] HealthTree Foundation
search person

Treatment Decision-Making for High-Risk MDS - HealthTree for MDS Webinar

Posted: Jun 03, 2024
Treatment Decision-Making for High-Risk MDS - HealthTree for MDS Webinar image

Getting a myelodysplastic syndrome (MDS) diagnosis can be overwhelming and often results in more questions than answers. Many patients can relate to the experience of getting home from their diagnosis appointment and not being able to remember much past the words, “You have cancer”.

Treatment Options and Decision-Making with Dr. Justin Taylor

In this patient webinar held on May 8th, 2024, we were privileged to have Dr. Justin Taylor, a renowned MDS specialist from the Sylvester Comprehensive Cancer Center. Dr. Taylor, with his vast experience and expertise, guided our high-risk MDS (HR-MDS) community through the intricacies of an MDS diagnosis, the factors that determine its risk level, and the decision-making process for treatments. He also discussed the current treatment options available and shared his enthusiasm about promising treatments under study. 

Q&A with an MDS Specialist

During the Q&A session, Dr. Tylor answered the following questions: 

  • [47:20] If I’m experiencing bad reactions to azacitidine, is it better to switch to decitabine?
  • [49:40] If a patient had very few side effects from azacitidine (Vidaza) injection and transfers to decitabine (Inqovi), would you expect the same little to no side effects?
  • [51:25] How does the patient decision-making process throughout high-risk MDS treatment look?
  • [55:50] Would risk stratification vary based on the doctor I see? Would doctors have different opinions on my risk status?
  • [58:00] My blasts went from 11% to 1% with azacitidine and venetoclax. Can I still get AML? How long will these drugs work for?

If you have been diagnosed with HR-MDS, watch the full recording to get a thorough overview of what HR-MDS is and what options you have available to you.

Watch the full recording here

Empowerment Through Education: HealthTree University for MDS

If you're eager to delve deeper into your MDS diagnosis, we highly recommend HealthTree University for MDS. This free, online video education series is taught by top MDS specialists from across the US, ensuring you have access to the most comprehensive and up-to-date information. Updated several times a year, HealthTree University for MDS covers all aspects of your diagnosis in an easy-to-understand format.

Start learning now; click here to get started! 

HEALTHTREE UNIVERSITY FOR MDS
 

Getting a myelodysplastic syndrome (MDS) diagnosis can be overwhelming and often results in more questions than answers. Many patients can relate to the experience of getting home from their diagnosis appointment and not being able to remember much past the words, “You have cancer”.

Treatment Options and Decision-Making with Dr. Justin Taylor

In this patient webinar held on May 8th, 2024, we were privileged to have Dr. Justin Taylor, a renowned MDS specialist from the Sylvester Comprehensive Cancer Center. Dr. Taylor, with his vast experience and expertise, guided our high-risk MDS (HR-MDS) community through the intricacies of an MDS diagnosis, the factors that determine its risk level, and the decision-making process for treatments. He also discussed the current treatment options available and shared his enthusiasm about promising treatments under study. 

Q&A with an MDS Specialist

During the Q&A session, Dr. Tylor answered the following questions: 

  • [47:20] If I’m experiencing bad reactions to azacitidine, is it better to switch to decitabine?
  • [49:40] If a patient had very few side effects from azacitidine (Vidaza) injection and transfers to decitabine (Inqovi), would you expect the same little to no side effects?
  • [51:25] How does the patient decision-making process throughout high-risk MDS treatment look?
  • [55:50] Would risk stratification vary based on the doctor I see? Would doctors have different opinions on my risk status?
  • [58:00] My blasts went from 11% to 1% with azacitidine and venetoclax. Can I still get AML? How long will these drugs work for?

If you have been diagnosed with HR-MDS, watch the full recording to get a thorough overview of what HR-MDS is and what options you have available to you.

Watch the full recording here

Empowerment Through Education: HealthTree University for MDS

If you're eager to delve deeper into your MDS diagnosis, we highly recommend HealthTree University for MDS. This free, online video education series is taught by top MDS specialists from across the US, ensuring you have access to the most comprehensive and up-to-date information. Updated several times a year, HealthTree University for MDS covers all aspects of your diagnosis in an easy-to-understand format.

Start learning now; click here to get started! 

HEALTHTREE UNIVERSITY FOR MDS
 

The author Mary Arnett

about the author
Mary Arnett

Mary joined HealthTree as the HealthTree for MDS Commnity Manager in 2022. She is passionate about giving power to patients through knowledge and health education. In her spare time, Mary loves attending concerts, spoiling her nieces and nephews, and experimenting in the kitchen.

newsletter icon

Get the latest thought leadership on your Myelodysplastic Syndromes delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.

Follow Us

facebook instagram youtube